Allen Capital Group’s Boston Scientific BSX Stock Holding History

Allen Capital Group’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,982	Closed	-$213K	–	268
2025 Q2	$213K	Buy	+1,982	New	+$201K	0.02%	255

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allen Capital Group's BSX Position: Q3 2025 in Review

Allen Capital Group sold out of Boston Scientific (BSX) in Q3 2025, closing a stake of 1,982 shares — an estimated $213K sold.

Allen Capital Group first reported a position in BSX in Q2 2025 and held it in 1 quarter. The position peaked at $213K in Q2 2025. 1,708 funds tracked by Wall St. Rank hold BSX as of Q3 2025.

Allen Capital Group reported no remaining Boston Scientific position as of Q3 2025 after selling out during the quarter.
Allen Capital Group sold 1,982 Boston Scientific shares in Q3 2025, an estimated $213K.
Allen Capital Group first reported a position in Boston Scientific in Q2 2025 and held it in 1 quarter.
Allen Capital Group's Boston Scientific position peaked at $213K in Q2 2025.
1,708 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2025.

Based on Allen Capital Group's 13F filing for Q3 2025, filed 27 Oct 2025.